Stay updated with breaking news from Targeted Augmentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions...
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that,...
– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study results and OLE data from patients receiving ongoing treatment; Analyses...
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 42nd Annual J.P....
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that...